Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DFV890 in familial cold autoinflammatory syndrome (FCAS)
2020-005948-33Phase 2Completed
- Sponsor
- Novartis
- Start
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of DFV890 in familial cold autoinflammatory syndrome (FCAS) and cryopyrin-associated periodic syndrome (CAPS), sponsored by Novartis. Primary endpoint: Change from baseline in white cell count. Started Feb 2021; status: completed.
02
Drugs
DFV890
03
Conditions
familial cold autoinflammatory syndrome (FCAS)cryopyrin-associated periodic syndrome (CAPS)
Beyond the preview
Go deeper on 2020-005948-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005948-33.